Form 4: Arcutis Director Exercises Options, Sells Shares

Arcutis Biotherapeutics Director Sue-Jean Lin exercised stock options and subsequently sold a portion of the acquired common stock on November 24, 2025.

Summary

• Director Sue-Jean Lin of Arcutis Biotherapeutics, Inc. executed transactions on November 24, 2025, involving the exercise of stock options and the sale of common stock.
• Exercised options for 18,052 shares of common stock at an exercise price of $8.63 per share.
• Exercised options for an additional 7,220 shares of common stock at an exercise price of $7.51 per share.
• Sold 25,272 shares of common stock at a weighted average price of $30.7833 per share, with individual sales ranging from $30.56 to $30.91.
• Following these transactions, Lin directly beneficially owns 26,735 shares of common stock.
• Remaining derivative securities include 9,000 stock options with an exercise price of $8.63 and an expiration date of June 14, 2034, and 5,000 stock options with an exercise price of $7.51 and an expiration date of May 31, 2033.

Sentiment

Score: 7

Explanation: The filing reports a routine insider transaction where a director exercised stock options and subsequently sold shares, realizing a profit. This is generally neutral for the company but positive for the individual director.

Positives

• Director Sue-Jean Lin realized a significant profit by selling shares at an average price of $30.7833 after exercising options at substantially lower prices ($8.63 and $7.51).

Negatives

• The sale of 25,272 shares by a director, while a common practice for option exercises, represents a reduction in direct insider ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction involves a director exercising options and selling shares, which is a common compensation event. It results in a slight increase in the public float and a reduction in the director's direct ownership, but typically has a neutral impact on the company's operational outlook.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director exercised stock options and subsequently sold a portion of the acquired shares. Such transactions are common for executive compensation and do not typically reflect a change in the company's fundamental prospects or the director's confidence in the long-term value of the company. Therefore, it does not provide a basis for a change in investment recommendation; a 'hold' stance remains appropriate based solely on this filing.

Keywords

Arcutis Biotherapeutics, ARQT, insider transaction, Form 4, stock options, common stock, director, Sue-Jean Lin, equity